Iodofiltic Acid I 123 use while Breastfeeding

Iodofiltic Acid I 123 Levels and Effects while Breastfeeding

Summary of Use during Lactation

Elective diagnostic nuclear medicine procedures should be delayed until the patient is no longer breastfeeding.[1] Information in this record refers to the use of iodofiltic acid I 123 (beta-methyl-15-(4-iodophenyl)pentadecanoic acid; I 123 BMIPP) as a diagnostic agent. The International Commission on Radiological Protection states that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 123 BMIPP. This usually will result in permanent discontinuation of breastfeeding for this infant. Mothers could ask to have their milk tested at a nuclear medicine facility at their hospital and when milk radioactivity will give the infant a dose below 1 mSv, they may safely resume breastfeeding.[2] A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[3]

Drug Levels

I 123 is a gamma emitter with a principal photon energy of 159 keV and a physical half-life of 13.2 hours.[3] Iodide is actively secreted into breastmilk and actively taken up by the mother's and infant's thyroid glands.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Possible Effects on Lactation

Relevant published information was not found as of the revision date.

References

1. Parker JA, Daube-Witherspoon ME, Graham LS et al. Procedure guideline for general imaging: 3.0. Society of Nuclear Medicine. 2004. http://interactive.snm.org/docs/General_Imaging_v3.0.pdf

2. ICRP. Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Annex D. Ann ICRP. 2008;38:163-84. PMID: 19154964

3. Howe DB, Beardsley M, Bakhsh S. Appendix U. Model procedure for release of patients or human research subjects administered radioactive materials. In, NUREG-1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. Final report. U.S. Nuclear Regulatory Commission Office of Nuclear Material Safety and Safeguards. 2008;9, Rev. 2. http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/r2/

Iodofiltic Acid I 123 Identification

Substance Name

Iodofiltic Acid I 123

CAS Registry Number

123748-56-1

Drug Class

Administrative Information

LactMed Record Number

808

Information from the National Library of Medicine's LactMed Database.

Last Revision Date

2013-09-07

Disclaimer

Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.

Hide
(web5)